Ensho
Online ISSN : 1884-4006
Print ISSN : 0389-4290
ISSN-L : 0389-4290
Development of passive immunization against periodontal disease
Preparations of recombinant ScFv and human type antibodies
Yoshimitsu Abiko
Author information
JOURNAL FREE ACCESS

1998 Volume 18 Issue 6 Pages 425-432

Details
Abstract
The use of immunoglobulin for human in vivo treatment has been limited to a great extent by the patient's immune response to non human antibodies in immunotherapy. Since it is hard to accepted the idea in public society that periodontal diseases cause death in humans, the development of safe antibodies in passive immunization is required. Several methods have been developed for the production of safe antibodies such as recombinant single chain Fv (ScFv) and human type antibodies. Porphyromonas gingivalis, a Gram-negative anaerobe, appears to be one of the most virulent microorganisms in relation to adult periodontitis. Coaggregation and hemagglutinin factors are important virulent factors in colonization on host tissues. This paper briefly introduces here the methods for preparation of safe immunoglobulins and summarizes our own attempts in preparations of ScFv and human type antibodies which are capable to inhibit the activities of coaggregation and hemagglutinin of P. gingivalis.
Content from these authors
© The Japanese Society of Inflammation and Regeneration
Previous article Next article
feedback
Top